PURPOSE: To assess the efficacy and toxicity of carboplatin, etoposide, and the bcl-2 antisense oligonucleotide oblimersen as initial therapy for extensive-stage small-cell lung cancer (ES-SCLC). bcl-2 has been implicated as a key factor in SCLC oncogenesis and chemotherapeutic resistance. PATIENTS AND METHODS: A 3:1 randomized phase II study was performed to evaluate carboplatin and etoposide with (arm A) or without oblimersen (arm B) in 56 assessable patients with chemotherapy-naïve ES-SCLC. Outcome measures including toxicity, objective response rate, complete response rate, failure-free survival, overall survival, and 1-year survival rate. RESULTS: Oblimersen was associated with slightly more grade 3 to 4 hematologic toxicity (88% v 60%; P = .05). Response rates were 61% (95% CI, 45% to 76%) for arm A and 60% (95% CI, 32% to 84%) for arm B. The percentage of patients alive at 1 year was 24% (95% CI, 12% to 40%) with oblimersen, and 47% (95% CI, 21% to 73%) without oblimersen. Hazard ratios for failure-free survival (1.79; P = .07) and overall survival (2.13; P = .02) suggested worse outcome for patients receiving oblimersen. These results hold when adjusted for other prognostic factors, such as weight loss, in multivariate regression analysis. CONCLUSION: Despite extensive data supporting a critical role for Bcl-2 in chemoresistance in SCLC, addition of oblimersen to a standard regimen for this disease did not improve any clinical outcome measure. Emerging data from several groups suggest that this lack of efficacy may be due to insufficient suppression of Bcl-2 in vivo. Additional evaluation of this agent in SCLC is not warranted.
RCT Entities:
PURPOSE: To assess the efficacy and toxicity of carboplatin, etoposide, and the bcl-2 antisense oligonucleotide oblimersen as initial therapy for extensive-stage small-cell lung cancer (ES-SCLC). bcl-2 has been implicated as a key factor in SCLC oncogenesis and chemotherapeutic resistance. PATIENTS AND METHODS: A 3:1 randomized phase II study was performed to evaluate carboplatin and etoposide with (arm A) or without oblimersen (arm B) in 56 assessable patients with chemotherapy-naïve ES-SCLC. Outcome measures including toxicity, objective response rate, complete response rate, failure-free survival, overall survival, and 1-year survival rate. RESULTS: Oblimersen was associated with slightly more grade 3 to 4 hematologic toxicity (88% v 60%; P = .05). Response rates were 61% (95% CI, 45% to 76%) for arm A and 60% (95% CI, 32% to 84%) for arm B. The percentage of patients alive at 1 year was 24% (95% CI, 12% to 40%) with oblimersen, and 47% (95% CI, 21% to 73%) without oblimersen. Hazard ratios for failure-free survival (1.79; P = .07) and overall survival (2.13; P = .02) suggested worse outcome for patients receiving oblimersen. These results hold when adjusted for other prognostic factors, such as weight loss, in multivariate regression analysis. CONCLUSION: Despite extensive data supporting a critical role for Bcl-2 in chemoresistance in SCLC, addition of oblimersen to a standard regimen for this disease did not improve any clinical outcome measure. Emerging data from several groups suggest that this lack of efficacy may be due to insufficient suppression of Bcl-2 in vivo. Additional evaluation of this agent in SCLC is not warranted.
Authors: Sally Hopkins-Donaldson; Richard Cathomas; A Paula Simões-Wüst; Stefanie Kurtz; Larisa Belyanskaya; Rolf A Stahel; Uwe Zangemeister-Wittke; Larisa Belyanskya Journal: Int J Cancer Date: 2003-08-20 Impact factor: 7.396
Authors: Anthony Raffo; Johnathan C Lai; C A Stein; Paul Miller; Steven Scaringe; Anastasia Khvorova; Luba Benimetskaya Journal: Clin Cancer Res Date: 2004-05-01 Impact factor: 12.531
Authors: B Jahrsdörfer; R Jox; L Mühlenhoff; K Tschoep; A Krug; S Rothenfusser; G Meinhardt; B Emmerich; S Endres; G Hartmann Journal: J Leukoc Biol Date: 2002-07 Impact factor: 4.962
Authors: C M Rudin; G A Otterson; A M Mauer; M A Villalona-Calero; R Tomek; B Prange; C M George; L Szeto; E E Vokes Journal: Ann Oncol Date: 2002-04 Impact factor: 32.976
Authors: Charles M Rudin; Mark Kozloff; Philip C Hoffman; Martin J Edelman; Robyn Karnauskas; Ronald Tomek; Livia Szeto; Everett E Vokes Journal: J Clin Oncol Date: 2004-03-15 Impact factor: 44.544
Authors: Leena Gandhi; D Ross Camidge; Moacyr Ribeiro de Oliveira; Philip Bonomi; David Gandara; Divis Khaira; Christine L Hann; Evelyn M McKeegan; Elizabeth Litvinovich; Philip M Hemken; Caroline Dive; Sari H Enschede; Cathy Nolan; Yi-Lin Chiu; Todd Busman; Hao Xiong; Andrew P Krivoshik; Rod Humerickhouse; Geoffrey I Shapiro; Charles M Rudin Journal: J Clin Oncol Date: 2011-01-31 Impact factor: 44.544
Authors: Stacy L Moulder; W Fraser Symmans; Daniel J Booser; Timothy L Madden; Cindy Lipsanen; Linda Yuan; Abenaa M Brewster; Massimo Cristofanilli; Kelly K Hunt; Thomas A Buchholz; James Zwiebel; Vicente Valero; Gabriel N Hortobagyi; Francisco J Esteva Journal: Clin Cancer Res Date: 2008-12-01 Impact factor: 12.531
Authors: Rathi N Pillai; Joseph Aisner; Suzanne E Dahlberg; John S Rogers; Robert S DiPaola; Seena Aisner; Suresh S Ramalingam; Joan H Schiller Journal: Cancer Chemother Pharmacol Date: 2014-05-24 Impact factor: 3.333
Authors: Christine L Hann; Vincent C Daniel; Elizabeth A Sugar; Irina Dobromilskaya; Sara C Murphy; Leslie Cope; Xue Lin; Jared S Hierman; Daniel L Wilburn; D Neil Watkins; Charles M Rudin Journal: Cancer Res Date: 2008-04-01 Impact factor: 12.701